Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis, an orphan disease, is a type of chronic lung condition characterized by a progressive and irreversible decline in lung function and scarring (fibrosis) of the lungs. There is no cure for IPF and there are currently no procedures or medications that can remove the scarring from the lungs.
According to research and consulting firm GlobalData’s latest report, the idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over US $900 million in 2015 to US $3.2 billion by 2025, representing a projected compound annual growth rate (CAGR) of 13.6%

Market Projection*

(in US$ Billions)